Literature DB >> 26623074

S-1 treatment leading to complete remission of advanced duodenal adenocarcinoma: A case report.

Lijun Wang1, Quanmao Song2, Jinpeng Li3, Xiaohua Chen2.   

Abstract

Primary duodenal adenocarcinoma (DA) is a rare malignant neoplasm, accounting for 1% of all gastrointestinal tract carcinomas. This is the case report of a 40-year-old male patient with a duodenal lesion detected on abdominal magnetic resonance imaging and diagnosed by endoscopy and biopsy as DA. Following surgical resection and histopathological examination, the tumor was confirmed as differentiated duodenal neuroendocrine carcinoma with liver metastasis (TxNxM1). The patient received 8 cycles of palliative chemotherapy with oxaliplatin and S-1 and achieved a clinically complete response, with a treatment-related toxicity profile that was considered as tolerable. Therefore, this regimen exhibited favorable efficacy and a tolerable toxicity profile for the treatment of DA in this case.

Entities:  

Keywords:  drug therapy; duodenal adenocarcinoma

Year:  2015        PMID: 26623074      PMCID: PMC4535076          DOI: 10.3892/mco.2015.607

Source DB:  PubMed          Journal:  Mol Clin Oncol        ISSN: 2049-9450


  15 in total

1.  Randomized phase II study comparing paclitaxel with S-1 vs. S-1 as first-line treatment in patients with advanced gastric cancer.

Authors:  X Wang; M L Wang; L Y Zhou; X Y Lu; J F Yang; H G Yu
Journal:  Clin Transl Oncol       Date:  2013-02-05       Impact factor: 3.405

2.  Oxaliplatin scale and National Cancer Institute-Common Toxicity Criteria in the assessment of chemotherapy-induced peripheral neuropathy.

Authors:  Anna-Liisa Kautio; Maija Haanpää; Hannu Kautiainen; Arto Leminen; Eija Kalso; Tiina Saarto
Journal:  Anticancer Res       Date:  2011-10       Impact factor: 2.480

3.  Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial.

Authors:  Jaffer A Ajani; Wuilbert Rodriguez; Gyorgy Bodoky; Vladimir Moiseyenko; Mikhail Lichinitser; Vera Gorbunova; Ihor Vynnychenko; August Garin; Istvan Lang; Silvia Falcon
Journal:  J Clin Oncol       Date:  2010-02-16       Impact factor: 44.544

4.  Chemotherapy in small bowel adenocarcinoma: 10-year experience of the British Columbia Cancer Agency.

Authors:  P Czaykowski; D Hui
Journal:  Clin Oncol (R Coll Radiol)       Date:  2007-03       Impact factor: 4.126

5.  A single-institution experience with 491 cases of small bowel adenocarcinoma.

Authors:  Thorvardur R Halfdanarson; Robert R McWilliams; John H Donohue; J Fernando Quevedo
Journal:  Am J Surg       Date:  2010-06       Impact factor: 2.565

6.  Phase II study of 5-fluorouracil, doxorubicin, and mitomycin C for metastatic small bowel adenocarcinoma.

Authors:  Michael K Gibson; Christina A Holcroft; Larry K Kvols; Daniel Haller
Journal:  Oncologist       Date:  2005-02

7.  S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial.

Authors:  Wasaburo Koizumi; Hiroyuki Narahara; Takuo Hara; Akinori Takagane; Toshikazu Akiya; Masakazu Takagi; Kosei Miyashita; Takashi Nishizaki; Osamu Kobayashi; Wataru Takiyama; Yasushi Toh; Takashi Nagaie; Seiichi Takagi; Yoshitaka Yamamura; Kimihiko Yanaoka; Hiroyuki Orita; Masahiro Takeuchi
Journal:  Lancet Oncol       Date:  2008-02-20       Impact factor: 41.316

8.  Small bowel cancer in the United States: changes in epidemiology, treatment, and survival over the last 20 years.

Authors:  Karl Y Bilimoria; David J Bentrem; Jeffrey D Wayne; Clifford Y Ko; Charles L Bennett; Mark S Talamonti
Journal:  Ann Surg       Date:  2009-01       Impact factor: 12.969

9.  Phase II study of capecitabine and oxaliplatin for advanced adenocarcinoma of the small bowel and ampulla of Vater.

Authors:  Michael J Overman; Gauri R Varadhachary; Scott Kopetz; Rosni Adinin; E Lin; Jeffrey S Morris; Cathy Eng; James L Abbruzzese; Robert A Wolff
Journal:  J Clin Oncol       Date:  2009-01-21       Impact factor: 44.544

10.  New perspectives in the treatment of advanced or metastatic gastric cancer.

Authors:  Gerardo Rosati; Domenica Ferrara; Luigi Manzione
Journal:  World J Gastroenterol       Date:  2009-06-14       Impact factor: 5.742

View more
  3 in total

1.  Salvage Chemotherapy by FOLFIRI Regimen for Poorly Differentiated Gastrointestinal Neuroendocrine Carcinoma.

Authors:  Keiji Sugiyama; Kazuhiro Shiraishi; Mariko Sato; Riko Nishibori; Kazuki Nozawa; Chiyoe Kitagawa
Journal:  J Gastrointest Cancer       Date:  2020-09-12

2.  Radical resection of a primary unresectable duodenal cancer after chemotherapy using S-1 and cisplatin: report of a case.

Authors:  Masaru Kanehira; Yasuro Futagawa; Kenei Furukawa; Hiroaki Shiba; Tadashi Uwagawa; Katsuhiko Yanaga
Journal:  Surg Case Rep       Date:  2017-02-21

3.  Diagnosis and Treatment of Synchronous Lymphoma and Digestive System Carcinoma: Report of Four Cases and Literature Review.

Authors:  Jingshu Meng; Huaxiong Pan; Xiaoqian Li; Tao Liu; Zijian Liu; Qiuhui Li; Yin Xiao; Xinxiu Liu; Gang Wu; Fang Zhu; Liling Zhang
Journal:  Front Oncol       Date:  2019-12-10       Impact factor: 6.244

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.